Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cell Line
- Medical
- Drug Discovery
- Disease
- Therapeutic
- Enzymes
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 286096
Whereas, the remaining part of the Technology, known as the University Technology, is owned by the University and ownership of the Licensee Technology and the University Technology is governed by a separate agreement between the University and the Licensee,
The University is granting to the Licensee an exclusive license to the University Technology.
The University grants an irrevocable, exclusive right and license in any and all Fields of Use, including the right to sub license to Affiliates or unrelated third parties, to the Licensed Patents and the University Technology to make, have made, use, sell, offer to sell, import and export, lease or otherwise dispose of Licensed Product in the Territory.
The technology shall mean Licensees Technology and University Technology, including but not limited to, multipotent postnatal derived progenitor cells, precursors, progeny or components thereof, products and information obtained from the foregoing, processes and products utilized in production or processing of any of the foregoing, methods of utilizing any of the foregoing, and any Trade Secret Information or know-how relating to the foregoing. The term Technology shall also include any invention involving multipotent postnatal derived progenitor cells (a) that is the result of research conducted.
Licensed Patent shall mean a Patent that claims as an invention one or more aspects of the Technology.
Licensed Product shall mean any Technology which is within the scope of one or more claims of a Licensed Patent and, but for the license granted in this Agreement, would infringe, constitute contributory infringement, or constitute inducement to infringe of one or more such claims when made by, made for, used, sold, offered for sale, imported, exported, leased, or otherwise disposed of by the Licensee.
Lysosomal storage disorders are a group of more than 40 recessive genetic diseases resulting in deficiencies in lysosomal acid hydrolases. Although individually rare, lysosomal storage disorders have a prevalence of 1 per 7700 live births. Such diseases include Gaucher's disease, Fabry disease, Niemann-Pick disease, mucopolysaccharidoses Type I through VII, Tay-Sachs disease, among many others. Loss of lysosomal enzyme activity results in the progressive accumulation of undegraded substrate within the lysosomes, resulting in engorgement of the organelle, subsequent cellular, tissue, and organ dysfunction, and often death. Lysosomal storage diseases affect multiple organ systems, many of them before birth, resulting in irreversible defects. Clinical treatments for metabolic storage disorders are limited to bone marrow transplantation and enzyme replacement therapy.
IPSCIO Record ID: 367267
Stem Cell shall mean an undifferentiated Cell capable of proliferation, self maintenance and the production of a large number of differentiated functional progeny.
Progenitor Cell shall mean an undifferentiated Cell capable of limited proliferation and the production of differentiated functional progeny.
Cell Line shall mean c-MycER Cells of clonal origin, differentiated by the integration site of the c-MycER Cell insert.
Cells shall mean cultures of neural Stem Cells to the full extent described or claimed in the Licensee Patent Rights and shall include all progeny and derivatives of such stem cells (including Progenitor Cells and their progeny and Stem Cells and their progeny) and “Cell†shall mean one of such cells.
Licensor c-MycER Cell Technology shall mean all know-how, data, biological materials, inventions and other proprietary information and technology owned or Controlled by Licensor and relating to the manufacture, sale, use or manipulation of c-MycER Cells.
Licensor Patent Rights shall mean
(a) the patents and patent applications (the Licensor Patents),
(b) any and all United States or foreign patents and patent applications corresponding to any of the foregoing patents and patent applications, whether now existing of hereafter filed,
(c) any provisionals, substitutions, divisionals, reissues, renewals, continuations, continuations-in-part (but only to the extent not directed to new matter), extensions (including patent term extensions), substitute applications and inventors’ certificates arising from, or based upon, any of the foregoing patents or patent applications, in respect of the foregoing;
(d) any patents issuing from any of the foregoing patent applications, and
(e) any issued patents now or hereafter owned or Controlled by Licensor or an Affiliate of Licensor to the extent necessary or useful for the manufacture, use or sale of any product or method utilizing c-MycER Cells or Licensor c-MycER Cell Technology in the Licensee Field.
Licensee Product shall mean any product or method utilizing c-MycER Cells, the manufacture, use, or sale of which, but for the license granted to Licensee hereunder, would infringe any Valid Claim of the Licensor Patent Rights.
IPSCIO Record ID: 248345
Lysosomal storage diseases are a group of about 50 rare inherited metabolic disorders that result from defects in lysosomal function.[1] Lysosomes are sacs of enzymes within cells that digest large molecules and pass the fragments on to other parts of the cell for recycling. This process requires several critical enzymes. If one of these enzymes is defective, because of a mutation, the large molecules accumulate within the cell, eventually killing it.
IPSCIO Record ID: 314340
The term Patent Rights means the patent applications and patents, including all related international filings, reissues, reexaminations, divisions, or continuations thereof and patent applications and any inventions, whether patented or not, which University owns or controls throughout the world, covering or related to the beta-glucuronidase product candidate.
Recombinant human beta-glucuronidase, or rhGUS, is an intravenous, or IV, enzyme replacement therapy for the treatment of mucopolysaccharidosis 7, or MPS 7, also known as Sly Syndrome. Patients with MPS 7 suffer from severe cellular and organ dysfunction that typically leads to death in the teens or early adulthood. MPS 7 is caused by a deficiency of the lysosomal enzyme beta-glucuronidase, which is required for the breakdown of certain complex carbohydrates known as glycosaminoglycans, or GAGs. The inability to properly break down GAGs leads to their accumulation in many tissues, resulting in a serious multi-system disease. There are currently no approved drug therapies for MPS 7.
Mucopolysaccharidosis type 7 (MPS 7) is an inherited metabolic disorder. Like other types of MPS disease, MPS 7 is caused by an enzyme deficiency in the processing of glycosaminoglycans (GAGs). In MPS 7, patients lack the enzyme, beta-glucuronidase, which is required for the degradation of the GAGs dermatan sulfate (DS), heparan sulfate (HS), and chondroitin 6 sulfate (CS).
Licensee is a biopharmaceutical company that provides patients products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.
IPSCIO Record ID: 363077
Licensor hereby grants to Licensee a sole and exclusive (even as to Licensor), royalty-bearing, worldwide license under the Licensor Patent Rights to make and use c-MycER Cells to research, develop, make, have made, use, have used, sell, have sold, offer for sale and import Licensee NCTs in the Licensee Discovery Field.
Licensor hereby grants to Licensee a non-exclusive, royalty-bearing, worldwide license, under the Licensor Patent Rights to research, develop, make, have made, use, have used, sell, have sold, offer for sale and import, Unregulated Cells in the Licensee Reagent Field.
Stem Cell shall mean an undifferentiated Cell capable of proliferation, self maintenance and the production of a large number of differentiated functional progeny.
Progenitor Cell shall mean an undifferentiated Cell capable of limited proliferation and the production of differentiated functional progeny.
Cell Line shall mean c-MycER Cells of clonal origin, differentiated by the integration site of the c-MycER Cell insert.
Cells shall mean cultures of neural Stem Cells to the full extent described or claimed in the Licensor Patent Rights and shall include all progeny and derivatives of such stem cells (including Progenitor Cells and their progeny and Stem Cells and their progeny) and “Cell†shall mean one of such cells.
Licensee NCT shall mean a non-cellular therapeutic molecule, i.e., a new chemical or biological molecule, identified or developed by Licensee through the practice of inventions claimed in or covered by one or more of the Licensor Patents or molecules derived therefrom, which identification or development occurred during the term of a Valid Claim of any such Licensor Patent.
Licensor Patent Rights shall mean
(a) the patents and patent applications (the Licensor Patents),
(b) any and all United States or foreign patents and patent applications corresponding to any of the foregoing patents and patent applications, whether now existing of hereafter filed,
(c) any provisionals, substitutions, divisionals, reissues, renewals, continuations, continuations-in-part (but only to the extent not directed to new matter), extensions (including patent term extensions), substitute applications and inventors’ certificates arising from, or based upon, any of the foregoing patents or patent applications, in respect of the foregoing;
(d) any patents issuing from any of the foregoing patent applications; and
(e) any issued patents now or hereafter owned or Controlled by Licensor or an Affiliate of Licensor to the extent necessary or useful for the manufacture, use or sale of
(i) a c-MycER Cell (including without limitation a product utilizing a c-Myc-ER Cell) identified or developed, in whole or in part, through the practice by Licensee or a sub-licensee of Licensee of inventions claimed in or covered by one or more of the Licensor Patents, or
(ii) a Licensee NCT.
Licensee Product shall mean a c-MycER Cell or a product utilizing a c-MycER Cell identified or developed, in whole or in part, through the practice by Licensee or a sub-licensee of Licensee of inventions claimed in or covered by one or more of the Licensor Patents, which practice occurred during the term of a Valid Claim of any such Licensor Patent.
Licensee Discovery Field shall mean use of c-MycER Cells for the research, discovery, screening and development of new non-cellular therapeutics for use in the treatment of any disease state or condition in humans.
Licensee Reagents Field shall mean use of Unregulated Cells for research and other non-clinical and non-therapeutic purposes (not including administration to humans).
